Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (July 22nd Preview)
-
Hypertriglyceridemia gene-silencing expansion
Arrowhead Pharmaceuticals’ plozasiran (Redemplo) delivered “best-case scenario” results in two late-stage trials aimed at expanding use in severe hypertriglyceridemia, the company said Wednesday. In the year-long studies in adults with severe hypertriglyceridemia, median triglycerides fell 79% and 81% with the under-the-skin once-every-three-month RNA interference therapy versus about 27% with placebo, Arrowhead reported. The program also assessed acute pancreatitis, a major risk driven by very high triglyceride levels. A pooled analysis showed acute pancreatitis events dropped 78% versus control arms. Arrowhead said safety and tolerability remained favorable, with no clinically meaningful liver-enzyme deterioration, no cases of abnormally low platelets, and no hypersensitivity signals. Arrowhead plans to formally ask U.S. regulators to add severe hypertriglyceridemia to the Redemplo label before year-end, positioning the genetic medicine for broader adoption beyond its current rare-disease indication.
-
Sickle cell setbacks and pipeline reshaping
Agios Pharmaceuticals ended development of its next-generation sickle cell drug tebapivat after Phase 2 results failed to demonstrate a differentiated profile, the company said. Agios’ decision adds to a series of sickle cell clinical setbacks for the category of pyruvate kinase activator therapies. Tebapivat, a second-generation oral activator, did not establish the level of differentiation required to continue, Agios said, and the company will halt the indication even as it advances other efforts. The failure also shifts attention to competing enzyme activators, particularly Novo Nordisk’s mitapivat (Pyrukynd), which remains the reference standard in the class, while investors increasingly look for evidence of clearer differentiation and registrational paths. The update reflects how hard it has been to maintain clinical momentum in sickle cell disease, where regulators and payers can be unforgiving on incremental efficacy and safety.
-
Chronic itch trial failure closes out Celldex’s program
Celldex Pharmaceuticals stopped investigating its mast cell-targeting antibody barzolvolimab in prurigo nodularis after a Phase 2 study missed efficacy on all endpoints, the company disclosed. The program discontinuation follows barzolvolimab’s broader chronic itch development plans and raises questions about the strength of the upcoming readouts investors were awaiting, particularly as the company prepares for additional dermatology decision points. Celldex indicated it will end development in the indication where the trial failed and will focus on other programs, while analysts have cited the poor outcome as a reminder of how difficult mast-cell biology can be to translate into durable clinical benefit. For the sector, the move further concentrates risk in chronic itch pipelines and increases pressure for stronger biomarker strategies and patient selection.
-
Summit’s ivonescimab pivotal outlook for FDA decision
Summit Therapeutics released updated two-year survival data for its Phase 3 HARMONi trial evaluating ivonescimab in non-small cell lung cancer, while the FDA decision clock remains active. The company’s follow-up data covers the longer-term course for Western patients, though the update provides limited context on how directly outcomes compare across geographies and treatment subgroups, according to the report. The FDA is still scheduled to make an approval decision for the therapy in the indication by Nov. 14. Investors are now weighing whether durability signals reinforce earlier efficacy and safety findings. With regulators focused on both endpoint confidence and overall benefit-risk, survival follow-up can be decisive in closing remaining gaps. The next milestone for Summit remains the FDA’s action, which will determine whether ivonescimab advances in a high-competition lung cancer market.
-
Psychedelics licensing expands U.S. MDMA development
Jupiter Neurosciences entered a licensing deal for PharmAla Biotech’s non-racemic MDMA asset ALA-002, granting Jupiter exclusive rights to develop the compound in the U.S. for neuropsychiatric disorders including PTSD and anxiety. Under the agreement, PharmAla receives $3.3 million upfront split between cash and Jupiter common stock, plus additional payments tied to dosing the first patient in a Phase 3 trial and to regulatory milestones. The parties also tied the transaction to a changing U.S. regulatory posture toward investigational psychedelic therapies. The deal also references existing government-sponsored clinical work using PharmAla’s MDMA supply through the Veterans Affairs Administration and the Defense Health Agency. For the sector, the Jupiter-PharmAla transaction adds another institutionalized pathway for MDMA programs in the U.S., in parallel with ongoing psychedelic development and heightened interest in PTSD and broader anxiety populations.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.